Skip to main content
QuestionsResearchTagsGuidelinesLeaderboard
tachyDx Research Portal

Research tagged [infectious-disease]

Every paper is generated from a real clinical discussion on tachyDx, peer-reviewed by verified physicians, and published with a unique TDX identifier. All contributors are credited.

DOIs registered viaCrossref
Published26Under ReviewFlagged
Clear filters

3 papers

TDX-2026-00022

Management of Probable Invasive Aspergillosis in Febrile Neutropenia in Resource-Variable Settings: A Synthesis of Expert Opinion and Pragmatic Strategies

Invasive aspergillosis (IA) represents a significant cause of morbidity and mortality in immunocompromised patients, particularly those with febrile neutropenia following intensive chemotherapy for acute myeloid leukemia. Current international guidelines advocate for voriconazole as first-line therapy for probable IA. However, the implementation of these recommendations is frequently challenged in resource-variable settings due to high drug costs, limited availability of advanced formulations, and lack of therapeutic drug monitoring (TDM) capabilities. This paper synthesizes expert clinical perspectives from a peer-vetted medical Q&A platform to address the practical dilemmas encountered in such environments. We explore the nuanced decision-making process concerning initial antifungal choice, the role of conventional amphotericin B deoxycholate with pragmatic modifications, and the criteria for escalating to combination therapy. The discussion highlights the critical need for context-specific strategies that balance evidence-based medicine with economic realities, aiming to optimize patient outcomes despite significant resource constraints. This synthesis provides valuable insights for clinicians navigating these complex scenarios.

A physician-only Q&A platform where verified medical doctors share clinical knowledge, debate evidence, and build the knowledge base the world needs.

Powered by

Platform

  • Questions
  • Research
  • Tags
  • Guidelines
  • Leaderboard
  • Report a Bug

Ecosystem

  • Teams
  • Sponsors
  • Hiring
  • Publishing
  • CME
  • Data

Company

  • About
  • Support
  • Privacy Policy
  • Terms of Service
  • Contact

© 2026 Aethryva Deeptech Pvt Ltd. All rights reserved.

Crossref Member
2 contributors 75 votes 9 Apr 2026

TDX-2026-00015

Diagnostic Framework for Fever of Unknown Origin in Immunocompetent Adults: A Peer-Reviewed Clinical Consensus

Background: Fever of Unknown Origin (FUO) in immunocompetent adults represents a significant diagnostic challenge, often requiring extensive investigation despite initial comprehensive workup. The lack of specific localizing symptoms and the broad differential diagnosis necessitate a systematic, tiered approach to avoid diagnostic delays and inappropriate empirical treatments. This paper synthesizes expert clinical opinions on the subsequent diagnostic steps following an unrevealing initial evaluation. Methods: This consensus paper was developed from a clinical Q&A discussion on the tachyDx community platform, involving three verified physicians (an internist, an infectious disease specialist, and an oncologist) and garnering 60 community peer votes. The original clinical scenario involved a 42-year-old female presenting with four weeks of fever, weight loss, and night sweats, with an extensive negative initial workup. Expert responses were analyzed and synthesized to formulate a structured diagnostic pathway. Results: Key recommendations for second-tier investigations include 18F-FDG PET/CT, which demonstrates a diagnostic yield of approximately 50% and guides targeted biopsies. Specific laboratory markers such as ferritin (>1000 ng/mL for adult-onset Still's disease), LDH, uric acid, and beta-2 microglobulin (for occult lymphoma) were highlighted. The importance of repeat blood cultures for fastidious organisms and targeted biopsies (bone marrow, temporal artery, liver, or excisional lymph node) based on imaging findings was emphasized. Empiric anti-tuberculosis treatment in endemic areas and empiric steroid therapy for adult-onset Still's disease were recommended only under strict clinical and laboratory criteria. Conclusions: A systematic, tiered diagnostic approach incorporating advanced imaging, specific biomarkers, and targeted biopsies is crucial for resolving FUO after an initial negative workup. Careful consideration of regional epidemiology and strict adherence to diagnostic criteria are paramount before initiating empiric therapies, particularly in conditions like tuberculosis and adult-onset Still's disease.

3 contributors 60 votes 6 Apr 2026

TDX-2026-00007

Optimizing Bedaquiline-Based Regimens for Pre-Extensively Drug-Resistant Tuberculosis in HIV Co-infection: A Community Peer-Reviewed Clinical Consensus

Background: Pre-extensively drug-resistant tuberculosis (pre-XDR TB), characterized by resistance to isoniazid, rifampicin, and fluoroquinolones, presents a significant global health challenge, particularly in individuals co-infected with human immunodeficiency virus (HIV). The advent of novel anti-TB agents and shorter regimens, such as bedaquiline-pretomanid-linezolid (BPaL), offers improved outcomes but necessitates careful consideration of regimen composition, drug dosing, adverse event monitoring, and drug-drug interactions. Methods: This study synthesizes expert clinical opinion derived from a peer-reviewed clinical Q&A platform (tachyDx), involving two verified physicians and garnering 54 community peer votes. A clinical scenario involving a 34-year-old female with pre-XDR TB and HIV co-infection was presented, prompting discussion on regimen selection, linezolid management, QTc monitoring, antiretroviral therapy (ART) timing, and drug interactions. The accepted answer and additional insights were critically analyzed to establish a consensus. Results: The BPaL regimen was strongly favored for its shorter duration and high efficacy, contingent on pretomanid availability. Optimal linezolid dosing was identified as 600 mg daily for 26 weeks, with rigorous hematologic and neurologic monitoring. A comprehensive QTc monitoring protocol for bedaquiline, particularly in the context of dolutegravir (DTG) co-administration, was outlined. Continuation of existing ART was recommended, with specific guidance for ART-naïve patients. Critical drug-drug interactions, including those involving CYP3A4 inhibitors/inducers and monoamine oxidase inhibitors, were highlighted. Conclusions: This expert consensus provides practical, evidence-informed guidance for managing pre-XDR TB in HIV co-infected patients, emphasizing the BPaL regimen, meticulous adverse event monitoring, and proactive management of drug interactions. These recommendations aim to facilitate the safe and effective implementation of novel TB therapies in complex clinical settings.

2 contributors 54 votes 6 Apr 2026
Page 1 of 2Next →

Topics

Allpharmacology8critical-care7cardiology6emergency-medicine6oncology5pulmonology5nephrology4neurology4gastroenterology3immunology3hematology3surgery3infectious-disease3radiology2endocrinology2anesthesiology2hepatology2pediatrics2rheumatology2evidence-based-medicine1orthopedics1trauma1neonatology1psychiatry1internal-medicine1